Adverum Biotechnologies, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 24.79 million compared to USD 29.06 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 2.9 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.655 USD | +0.99% | -18.38% | -12.29% |
Jun. 11 | Adverum Biotechnologies, Inc. Announces Executive Changes | CI |
May. 16 | Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.29% | 137M | |
+16.16% | 121B | |
+18.88% | 112B | |
+4.43% | 22.57B | |
-18.13% | 20.82B | |
-14.10% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.76% | 13.17B | |
+25.68% | 11.11B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024